FDA labeling notes postmarketing reports of acute kidney injury in patients treated with semaglutide, the majority in people who had gastrointestinal reactions leading to dehydration, and it instructs patients to promptly report persistent nausea, vomiting, or diarrhea to their healthcare provider
For weight management, NHS GLP-1 treatment must be initiated and supervised by specialist weight management services, not primary care alone, following NICE guidance and local commissioning pathways
Greco M, Chiefari E, Montalcini T, et al
Current evidence suggests these medications do not directly cause clinically significant bone loss, though the substantial weight reduction they produce may indirectly influence bone metabolism
Zawada, Zbigniew
VAT plus Shipping Costs Delivery time: 16 Working Days SS-31 (Elamipretide) Peptide Login to see prices incl